TCI Wealth Advisors’s Anika Therapeutics ANIK Stock Holding History

TCI Wealth Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-134	Closed	-$3.85K	–	315
2023 Q1	$3.85K	Hold	134	–	–	﹤0.01%	1711
2022 Q4	$3.97K	Buy	+134	New	+$3.81K	﹤0.01%	1681
2018 Q4	–	Sell	-29	Closed	-$1K	–	1435
2018 Q3	$1K	Hold	29	–	–	﹤0.01%	1150
2018 Q2	$1K	Hold	29	–	–	﹤0.01%	1233
2018 Q1	$1K	Hold	29	–	–	﹤0.01%	1079
2017 Q4	$2K	Hold	29	–	–	﹤0.01%	984
2017 Q3	$2K	Hold	29	–	–	﹤0.01%	921
2017 Q2	$1K	Hold	29	–	–	﹤0.01%	1085
2017 Q1	$1K	Hold	29	–	–	﹤0.01%	1033
2016 Q4	$1K	Hold	29	–	–	﹤0.01%	1114
2016 Q3	$1K	Hold	29	–	–	﹤0.01%	1073
2016 Q2	$2K	Hold	29	–	–	﹤0.01%	904
2016 Q1	$1K	Buy	+29	New	+$1.18K	﹤0.01%	1039

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TCI Wealth Advisors's ANIK Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Anika Therapeutics (ANIK) in Q2 2023, closing a stake of 134 shares — an estimated $3.85K sold.

TCI Wealth Advisors first reported a position in ANIK in Q1 2016 and held it in 13 quarters. The position peaked at $3.97K in Q4 2022. 117 funds tracked by Wall St. Rank hold ANIK as of Q2 2023.

TCI Wealth Advisors reported no remaining Anika Therapeutics position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 134 Anika Therapeutics shares in Q2 2023, an estimated $3.85K.
TCI Wealth Advisors first reported a position in Anika Therapeutics in Q1 2016 and held it in 13 quarters.
TCI Wealth Advisors's Anika Therapeutics position peaked at $3.97K in Q4 2022.
117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.